Phase I trial of PTK787/ZK222584 (PTK/ZK) in combination with carboplatin (C) and paclitaxel (T) in platinum-sensitive recurrent epithelial ovarian (EOC), fallopian tube (FT), or primary peritoneal (PPC) cancers

被引：0
|
作者：
Juretzka, M. M. [1 ]
Aghajanian, C. [1 ]
Hensley, M. L. [1 ]
Tew, W. P. [1 ]
Spriggs, D. [1 ]
Konner, J. [1 ]
Chiang, A. C. [1 ]
Pezzulli, S. [1 ]
Kim, M. [1 ]
Sabbatini, P. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5564
引用
收藏
页数：2
相关论文
共 31 条
  • [21] Phase I study of carboplatin (C), pegylated liposomal doxorubicin (PLD) and everolimus (E) in platinum-sensitive epithelial ovarian, Fallopian tube or primary peritoneal cancer in first relapse (NCT01281514).
    Martin, Lainie P.
    Jain, Angela
    Chu, Christina
    Mantia-Smaldone, Gina
    Rubin, Stephen C.
    Ross, Eric A.
    Schilder, Russell J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab, and veliparib (ABT-888) in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: A Gynecologic Oncology Group study
    Landrum, L. M.
    Brady, W. E.
    Armstrong, D. K.
    Moore, K. N.
    DiSilvestro, P. A.
    O'Malley, D. M.
    Tenney, M. E.
    Rose, P. G.
    Fracasso, P. M.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 23 - 23
  • [23] UPDATED OVERALL SURVIVAL ANALYSIS IN OCEANS, A RANDOMIZED PHASE 3 TRIAL OF GEMCITABINE (G) plus CARBOPLATIN (C) AND BEVACIZUMAB (BV) OR PLACEBO (PL) FOLLOWED BY BV OR PL IN PLATINUM-SENSITIVE RECURRENT EPITHELIAL OVARIAN (ROC), PRIMARY PERITONEAL (PPC), OR FALLOPIAN TUBE CANCER (FTC)
    Aghajanian, C.
    Nycum, L. R.
    Goff, B.
    Nguyen, H.
    Husain, A.
    Blank, S. V.
    ANNALS OF ONCOLOGY, 2012, 23 : 319 - 319
  • [24] Phase Ib study of AMG 386 in combination with paclitaxel (P) and carboplatin (C) in high-risk stage I and stages II-IV epithelial ovarian, primary peritoneal, or fallopian tube cancers.
    Casado, Antonio
    Oaknin, Ana
    Baurain, Jean-Francois
    Wong, Shirley S.
    Yang, Xinqun
    Wu, Benjamin
    Zhong, Zhandong Don
    Puhlmann, Markus
    Vergote, Ignace B.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] Efficacy in Patient Subgroups in OCEANS, a Randomized, Double-blinded, Placebo-controlled, Phase 3 Trial of Chemotherapy ± Bevacizumab in Patients with Platinum-sensitive Recurrent Epithelial Ovarian (OC), Primary Peritoneal (PPC), or Fallopian Tube Cancer (FTC)
    Aghajanian, C.
    Blank, S. V.
    Goff, B.
    Judson, P. L.
    Makhija, S.
    Sharma, S. K.
    Nycum, L. R.
    Yi, J.
    Husain, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : 5 - 5
  • [26] Results from a 2nd interim OS analysis in OCEANS: A randomized phase 3 trial of gemcitabine (G), carboplatin (C) and bevacizumab (BV) followed by BV to disease progression in patients with platinum-sensitive recurrent epithelial ovarian (OC), primary peritoneal (PPC), or fallopian tube cancer (FTC)
    Aghajanian, C.
    Blank, S.
    Goff, B.
    Judson, P.
    Nycum, L.
    Sovak, M.
    Yi, J.
    Husain, A.
    GYNECOLOGIC ONCOLOGY, 2012, 125 (03) : 773 - 773
  • [27] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    Aghajanian, Carol
    Blank, Stephanie V.
    Goff, Barbara A.
    Judson, Patricia L.
    Teneriello, Michael G.
    Husain, Amreen
    Sovak, Mika A.
    Yi, Jing
    Nycum, Lawrence R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) : 2039 - 2045
  • [28] A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213)
    Coleman, R. L.
    Brady, M. F.
    Herzog, T. J.
    Sabbatini, P.
    Armstrong, D. K.
    Walker, J. L.
    Kim, B. G.
    Fujiwara, K.
    Tewari, K. S.
    O'Malley, D. M.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 3 - 4
  • [29] A randomized, placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum-resistant epithelial ovarian, primary peritoneal, or Fallopian tube cancers: Trial of Princess Margaret, Mayo, Chicago, and California consortia.
    Lheureux, Stephanie
    Weberpals, Johanne Ingrid
    Hendrickson, Andrea Elisabeth Wahner
    Fleming, Gini F.
    Olawaiye, Alexander
    Brana, Irene
    Mackay, Helen
    Dhani, Neesha C.
    Wilson, Michelle K.
    Rodriguez-Freixinos, Victor
    Martin-Lorente, Cristina
    Ward, Jacklyn
    Chang, Karen
    Wang, Lisa
    Speers, Vanessa
    Karakasis, Katherine
    Bowering, Valerie Lydia
    Chen, Alice
    Brenton, James
    Oza, Amit M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma.
    Bookman, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 256S - 256S
1234